AbbVie to Acquire Capstan Therapeutics, Expanding Commitment to Innovative Immunology Care
Reuters
Jun 30, 2025
AbbVie to Acquire Capstan <a href="https://laohu8.com/S/LENZ">Therapeutics</a>, Expanding Commitment to Innovative Immunology Care
AbbVie Inc. announced its agreement to acquire Capstan Therapeutics, a biotechnology company specializing in in vivo engineering of cells through RNA delivery using targeted lipid nanoparticles (tLNPs). AbbVie will pay up to $2.1 billion in cash for the acquisition. This transaction includes Capstan's lead asset, CPTX2309, an anti-CD19 CAR-T therapy candidate currently in Phase 1, aimed at treating B cell-mediated autoimmune diseases. The acquisition also involves Capstan's proprietary tLNP platform technology, which is designed to deliver RNA payloads such as mRNA to specific cell types in vivo. Laura Shawver, Ph.D., president and CEO of Capstan, highlighted the potential of in vivo CAR-T as a new treatment modality that combines the transformative power of cell therapy with the accessibility of an off-the-shelf biologic. Shawver emphasized the shared mission with AbbVie to advance these innovative therapies to patients in need.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CG20890) on June 30, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.